MyFinsight
Home
Compare
Blog
About
Attovia Therapeutics, Inc. (ATTO)
Attovia Therapeutics, Inc. (ATTO)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Free Cash flow
-$35,293K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Accounts payable
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Payments of deferred offering co...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
Net loss
-39,343
Stock-based compensation expense
1,378
Depreciation expense
488
Net accretion of discounts on marketable securities
346
Non-cash lease expense
795
Change in fair value of preferred stock tranche liability
0
Loss on disposal of property and equipment
0
Write-off of deferred offering costs
0
Prepaid expenses and other current assets
-972
Accounts payable
3,159
Accrued and other current liabilities
-1,124
Operating lease liability
-936
Other non-current assets
-25
Net cash used in operating activities
-34,932
Maturities of marketable securities
77,900
Purchases of marketable securities
48,174
Purchases of property and equipment
361
Net cash provided by (used in) investing activities
29,365
Proceeds from issuance of common stock upon exercise of stock options
42
Payments of deferred offering costs
1,839
Proceeds from issuance of convertible preferred stock, net of issuance costs-Series BPreferred Stock
0
Proceeds from issuance of convertible preferred stock, net of issuance costs-Series CPreferred Stock
0
Net cash (used in) provided by financing activities
-1,797
Net change in cash, cash equivalents and restricted cash
-7,364
Cash, cash equivalents and restricted cash at the beginning of the period
40,597
Cash, cash equivalents and restricted cash at the end of the period
33,233
Deferred offering costs in accounts payable and accrued and other current liabilities
709
Vesting of early exercised stock options
78
Property and equipment purchases in accounts payable
6
Accretion of redeemable convertible preferred stock to its redemption value
0
Right-of-use asset obtained in exchange for operating lease liability
0
Settlement of preferred stock tranche liability upon issuance of series b redeemable convertible preferred stock
0
Cash and cash equivalents
32,829
Restricted cash
404
Total cash, cash equivalents and restricted cash
33,233
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$77,900K
Net cash provided by
(used in) investing...
$29,365K
Canceled cashflow
$48,535K
Net change in cash,
cash equivalents and...
-$7,364K
Canceled cashflow
$29,365K
Accounts payable
$3,159K
Stock-based compensation
expense
$1,378K
Prepaid expenses and
other current assets
-$972K
Non-cash lease expense
$795K
Depreciation expense
$488K
Other non-current
assets
-$25K
Proceeds from issuance of
common stock upon...
$42K
Purchases of marketable
securities
$48,174K
Purchases of property and
equipment
$361K
Net cash used in
operating activities
-$34,932K
Canceled cashflow
$6,817K
Net cash (used in)
provided by financing...
-$1,797K
Canceled cashflow
$42K
Net loss
-$39,343K
Accrued and other
current liabilities
-$1,124K
Operating lease liability
-$936K
Net accretion of
discounts on marketable...
$346K
Payments of deferred
offering costs
$1,839K
Buy us a coffee